Damm, M.; Efremov, L.; Birnbach, B.; Terrero, G.; Kleeff, J.; Mikolajczyk, R.; Rosendahl, J.; Michl, P.; Krug, S.
Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis. Cancers 2021, 13, 4326.
https://doi.org/10.3390/cancers13174326
AMA Style
Damm M, Efremov L, Birnbach B, Terrero G, Kleeff J, Mikolajczyk R, Rosendahl J, Michl P, Krug S.
Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis. Cancers. 2021; 13(17):4326.
https://doi.org/10.3390/cancers13174326
Chicago/Turabian Style
Damm, Marko, Ljupcho Efremov, Benedikt Birnbach, Gretel Terrero, Jörg Kleeff, Rafael Mikolajczyk, Jonas Rosendahl, Patrick Michl, and Sebastian Krug.
2021. "Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis" Cancers 13, no. 17: 4326.
https://doi.org/10.3390/cancers13174326
APA Style
Damm, M., Efremov, L., Birnbach, B., Terrero, G., Kleeff, J., Mikolajczyk, R., Rosendahl, J., Michl, P., & Krug, S.
(2021). Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis. Cancers, 13(17), 4326.
https://doi.org/10.3390/cancers13174326
